Turn.Bio

Turn Biotechnologies, a biotechnology firm, is centered on the development of medicines to reverse aging and address age-related diseases. The company was founded by a team of experienced scientists and entrepreneurs, including Anja Krammer, who serves as the CEO, and Marco Quarta, a specialist in aging and regenerative medicine.

Krammer, a veteran of Fortune 500 companies and co-founder of three startups in Silicon Valley, has a track record of guiding companies through evolution and growth, including taking them public. Quarta, a research scientist and serial entrepreneur, has founded or co-founded three companies and is an expert in the field of aging.

Turn Biotechnologies has developed a proprietary platform called ERA™ (Epigenetic Reprogramming of Aging), which uses mRNA to produce proteins that are capable of reprogramming cells. This technology is designed to restore the youthful vigor of cells and repair damage caused by the aging process. The company's initial focus is on dermatology, with future applications planned for immunology, ophthalmology, and musculature.

The company's business model is focused on the research and development of these novel therapies. They aim to address multiple aging-related indications with a single reprogramming therapy. Turn Biotechnologies has expanded its capabilities through strategic acquisitions, including a therapeutic delivery technology developed at Harvard University. The company has also secured investments from firms like HanAll Biopharma and Daewoong Pharmaceutical, which will support the advancement of its research and clinical development programs.

Keywords: cellular reprogramming, mRNA medicines, longevity, biotechnology, aging, regenerative medicine, epigenetic reprogramming, dermatology, immunology, ophthalmology